Navigation Links
Tianyin Reports Record Fiscal 2010 Financial Results
Date:9/29/2010

ns 14,746,137 9,716,595 Other income (expenses): Interest (expense) income, net (26,649) 261,463 Impairment loss on intangible assets -- (431,344) Other expenses (39,518) -- Total other expenses (65,167) (169,881) Income before provision for income taxes 14,680,970 9,546,714 Provision for income taxes 2,626,143 1,639,104 Net income 12,054,827 7,907,610 Less: Net income attributable to noncontrolling interest 11,677 -- Net income attributable to Tianyin Pharmaceutical Co., Inc. 12,043,150 7,907,610 Other comprehensive income Foreign currency translation adjustment 293,696 73,506 Comprehensive income $12,336,846 $7,981,116 Basic earnings per share $0.47 $0.41 Diluted earnings per share $0.40 $0.32 Weighted average number of common shares outstanding: Basic 24,427,329 15,937,411 Diluted 30,081,685 24,805,281 Consolidated Statements of Cash Flows For the Years Ended June 30, 2010 2009 Cash flows from operating activities: Net Income $12,043,150 $7,907,610 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 953,767 676,605 Provision for bad debts 247,131 81,512 Loss on disposal of fixed assets 39,518 -- Impairment loss on intangible assets -- 431,344 Stock-based payments 1,037,686 249,026 Noncontrolling interest 11,677 -- Changes in current assets and current liabilities: Accounts receivable (2,770,322) (1,223,282) Inventory 239,233 (237,975) Other current assets 606,785 (62,705) Accounts payable and accrued expenses 315,202 49,867 Accounts payable - construction related 2,239,231 -- VAT taxes payable 222,833 180,701 Income tax payable 366,845 147,897 Other taxes payable (19,223) (28,213) Dividend payable (252,422) -- Other current liabilities 119,007 164,611 Total adjustments 3,356,948 429,388 Net cash provided by operating activities 15,400,098 8,336,998 Cash flows from investing activities: Loans receivable (293,340) -- Additions to property and equipment (59,946) (58,014) Additions to construction
'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Tianyin Corporate Presentation Updated
2. Tianyin Reports Record Third Quarter 2010 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
4. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
5. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
9. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... on health care, Jack Uldrich has been selected ... in New York today. He will deliver his ... , Uldrich has delivered presentations to the American ... of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3
... Nov. 24 Terumo Heart, Inc. is pleased to,announce ... Chief Executive,Officer (C.E.O.) and President, effective immediately. "With its ... leadership role in,the future treatment of heart failure. I ... DuraHeart U.S. Pivotal trials in up to 40 clinical ...
... LAKE, N.J., Nov. 24 Eisai Inc., in ... of the,C.A.R.E. (Commitment to Alzheimer,s. Recognition of Excellence.) ... pharmacist who has been,nominated by a person with ... her,exceptional impact on the lives of those fighting ...
... companies serving biotech/pharma industry to find new business opportunities and ... ... (PRWEB) November 24, 2008 -- In response to challenging economic ... its PharmSource Lead Sheet, a weekly web-based service that reports ...
Cached Biology Technology:Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 3PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma 2
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... In a new study published in the August 16th ... Medical Center identified a molecular mechanism that guarantees that new ... proper abundance. "We have known for a long time ... and that in some places of our bodies this branching ...
... CORVALLIS, Ore. A recent study suggests that parasites ... have more profound impacts on fish health than has been ... which habitat and land use changes cause salmon mortality. ... is important, the research found, but their numbers that can ...
... TORONTO, August 15, 2011 A study out of ... be good for you. Published today in the journal ... that obese people who are otherwise healthy live just as ... die of cardiovascular causes. "Our findings challenge the ...
Cached Biology News:Parasite loads an underlying cause of salmon mortality, linked to land use changes 2Fat and healthy? York U study finds slim isn't always superior 2
... Edited by R. Edwards (1996) ... all types of immunoassays, including ... immunoassays and on the photoluminescent ... Essential information is also given ...
EoProbe Eosinophil Staining Kit, 1 Kit...
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: